Showing 2221-2230 of 9355 results for "".
- Dr. Shawn Kwatra Analyzes ADtouch Data on Hand and Foot Atopic Dermatitishttps://practicaldermatology.com/news/dr-shawn-kwatra-analyzes-adtouch-data-on-hand-and-foot-atopic-dermatitis/2488634/New Phase 3b ADtouch data for lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) may help broaden how dermatologists assess disease burden in patients with atopic dermatitis (AD) affecting high-impact areas, according to study investigator Shawn Kwatra, MD.
- Dr. Alexa Kimball Highlights Early Response, HiSCR75 Findings With Tulisokibart in Hidradenitis Suppurativahttps://practicaldermatology.com/news/dr-alexa-kimball-highlights-early-response-hiscr75-findings-with-tulisokibart-in-hidradenitis-suppurativa/2488609/New Phase 2b data for tulisokibart may provide early clinical evidence supporting tumor necrosis factor-like cytokine 1A (TL1A) as a therapeutic target in hidradenitis suppurativa (HS), according to study investigator Alexa Kimball, MD, MPH.
- Delgocitinib Shows Real-World and Adolescent CHE Outcomes: Studyhttps://practicaldermatology.com/news/eadv-2026-delgocitinib-shows-real-world-and-adolescent-che-outcomes/2488596/LEO Pharma presented new delgocitinib cream data at the 35th European Academy of Dermatology and Venereology (EADV) Congress, including interim real-world findings in adults and post hoc phase 3 analyses examining symptoms and quality of life in adolescents with moderate to
- Kenvue Presents New Skin and Hair Research at EADV 2026https://practicaldermatology.com/news/kenvue-presents-new-skin-and-hair-research-at-eadv-2026/2488594/New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 examines topical formulations containing niacinamide, trehalose, colloidal oat, and minoxidil across several skin and hair concerns. Kenvue announced 12 data sets invol
- Three-Year Data Detail Bimekizumab Outcomes in Hidradenitis Suppurativahttps://practicaldermatology.com/news/three-year-data-detail-bimekizumab-outcomes-in-hidradenitis-suppurativa/2488593/New analyses of the Phase 3 BE HEARD clinical program presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 evaluated long-term inflammatory lesions, tunnels, quality of life, and safety with bimekizumab (Bimzelx; UCB) in adults with moderate
- Lebrikizumab Improves Hand and Foot AD in Phase 3b ADtouch Trialhttps://practicaldermatology.com/news/lebrikizumab-improves-hand-and-foot-ad-in-phase-3b-adtouch-trial/2488591/Lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) improved skin clearance, itch, and pain compared with placebo among adults and adolescents with moderate-to-severe atopic dermatitis (AD) affecting the hands and feet, according to Phase 3b ADtouch results presented at the
- New LATITUDE Data Detail Zasocitinib Efficacy, Durability in Plaque Psoriasishttps://practicaldermatology.com/news/new-latitude-data-detail-zasocitinib-efficacy-durability-in-plaque-psoriasis/2488590/New Phase 3 data presented at the European Academy of Dermatology & Venereology (EADV) Congress 2026 showed higher skin clearance rates with investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) compared with deucravacitinib in adults with modera
- Olumiant Gains FDA Approval for Severe Alopecia Areata in Patients 12 and Olderhttps://practicaldermatology.com/news/olumiant-gains-fda-approval-for-severe-alopecia-areata-in-patients-12-and-older/2488595/The FDA has approved Eli Lilly and Company’s Olumiant (baricitinib) for patients aged 12 years and older with severe alopecia areata (AA), expanding the oral Janus kinase (JAK) inhibitor’s US indication to adolescents, according to an announcement from the manufacturer. The
- Simone Biles Shares Seborrheic Dermatitis, Eczema Journey in New Arcutis Campaignhttps://practicaldermatology.com/news/simone-biles-shares-seborrheic-dermatitis-eczema-journey-in-new-arcutis-campaign/2488580/Arcutis has partnered with World Champion gymnast Simone Biles to launch Skin to Believe In, an awareness campaign focused on seborrheic dermatitis and atopic dermatitis, according to a press release from the company. The campaign centers on Biles’ experience managin
- Incyte Previews Atopic Dermatitis, HS, Vitiligo Data for EADV 2026https://practicaldermatology.com/news/incyte-previews-atopic-dermatitis-hs-vitiligo-data-for-eadv-2026/2488546/Incyte will present new research spanning several immune-mediated skin diseases at the European Academy of Dermatology and Venereology (EADV) Congress 2026, scheduled for September 30 to October 3 in Vienna, Austria. Rather than focusing on a single disease or development program, the comp